

Sinusitis

CHI Formulary Treatment algorithm

Treatment algorithm-
March 2025

Supporting treatment
algorithms for the clinical
management of Sinusitis


Figure 1 outlines the Management algorithm of adults with acute rhinosinusitis

Figure 2 outlines the Management algorithm of adults with chronic rhinosinusitis aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

Figure 3 outlines the Saudi Ministry of Health Algorithm for the management of acute bacterial Rhinosinusitis

For further evidence, please refer to CHI **Sinusitis** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at <https://www.chi.gov.sa/knowledge-center/health-insurance-policies/pages/idf.aspx>


Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.



*INCS: **Intranasal Corticosteroid**

Figure 1. Management algorithm of adults with acute rhinosinusitis

¹ Rhinosinusitis. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. <https://empendium.com/mcmtextbook/chapter/B31.II.3.2>. For the level of evidence and details on the figures in the algorithm, please refer to the full report.




2

CRSsNP: Chronic Rhinosinusitis without nasal polyps. **CRSwNP:** Chronic Rhinosinusitis with nasal polyps. **INCS:** Intranasal Corticosteroid

Figure 2. Management algorithm of adults with chronic rhinosinusitis

² Rhinosinusitis. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. <https://empendium.com/mcmtextbook/chapter/B31.II.3.2>. For the level of evidence and details on the figures in the algorithm, please refer to the full report.



3

Figure 3: **Saudi Ministry of Health Algorithm for the management of acute bacterial Rhinosinusitis**

³ Saudi Ministry of Health. Rhinosinusitis Treatment Protocol.; 2022.